MUCOLIPIDOSIS TYPE IV FOUNDATION INC (EIN 133633501) - Form 990 Financial Analysis & Trantor Score

🔒

Tuckman-Chang Vulnerability Assessment

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1982

Legal Domicile

Phone

8776545459

Tax Period

2023-01-01 to 2023-12-31

MUCOLIPIDOSIS TYPE IV FOUNDATION INC, founded in 1982, is a small nonprofit in the Diseases & Disorders sector that reported $653K in total revenue in fiscal year 2020. Revenue decreased 17% compared to the prior year. The organization ran a surplus of $210K, a strong 32% operating margin.

Mission

THE MUCOLIPIDOSIS TYPE IV FOUNDATION OPERATES TO RAISE CONTRIBUTIONS FROM INDIVIDUALS AND COMPANIES IN ORDER TO FUND MEDICAL RESEARCH GRANTS TO FIND A CURE FOR THIS DISEASE.

🔒

Trantor Score

Financial Health & Payment Capacity Assessment (FICO Scale: 300–850)

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $1,080,997

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $1,080,997

Expense Breakdown

Grants Paid $186,485

Salaries & Benefits $231,597

Fundraising Expenses $12,400

Program Expenses $533,499

Other Expenses $238,113

TOTAL EXPENSES $656,195

Year-over-Year Comparison

	2023	2022	Change
Revenue	$1,080,997	$860,271	+0.3%
Expenses	$656,195	$653,162	+0.0%
Net Income	$424,802	$207,109	+1.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

$197,833

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RANDY GOLD	PRESIDENT TREASURER	5.00	Officer Director	$0	$0	$0
CAROLINE GOLD	SECRETARY	2.00	Officer Director	$0	$0	$0
PAULA KUTNER	BOARD MEMBER	2.00	Director	$0	$0	$0
MICHAEL FRIEDMAN	BOARD MEMBER	2.00	Director	$0	$0	$0
DEBRA GOLDSCHMIDT	BOARD MEMBER	2.00	Director	$0	$0	$0
NATHANIEL FERNHOFF	BOARD MEMBER	2.00	Director	$0	$0	$0
REBECCA OBERMAN	EXECUTIVE DIRECTOR	40.00	Key Emp Highest	$197,833	$0	$197,833

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$1,080,997	$656,195	$1,477,459	$424,802
2022	$860,271	$653,162	$1,047,509	$207,109
2021	$676,492	$715,602	$839,865	$-39,110
2020	$652,541	$442,280	$905,712	$210,261

MUCOLIPIDOSIS TYPE IV FOUNDATION INC